Tumor size and prognosis in aggressively treated osteosarcoma

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 848-858

  Bieling, P ^a   Rehan, N ^a   Winkler, P ^a   Helmke, K ^a   Maas, R ^a   Fuchs, N ^a   Bielack, S ^a   Heise, U ^a   Jurgens, H ^a   Treuner, J ^a   Romanowski, R ^a   Exner, U ^a   Kotz, R ^a   Winkler, K ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS POTENTIAL; MULTICENTER STUDY; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TUMOR VOLUME;

EID: 9044249330     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.848     Document Type: Article

References (38)

1. McKenna RJ, Schwinn CP, Soong KY, et al: Osteosarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma and sarcomata arising in the normal bone). J Bone Joint Surg Am 48-A:1-26, 1966
2. Broström LA, Strander H, Nilsonne U: Survival in osteosarcoma in relation to tumor size and location. Clin Orthop 250-254, 1982
3. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606, 1986
4. Eilber F, Giuliano A, Eckardt J, et al: Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol 5:21-26, 1987
5. Winkler K, Beron G, Kotz R, et al: Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 2:617-624, 1984
6. Weiner MA, Harris MB, Lewis M, et al: Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. Cancer Treat Rep 70:1431-1432, 1986
7. Bacci G, Springfield D, Capanna R, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremity. Clin Orthop 268-276, 1987
8. Winkler K, Beron G, Delling G, et al: Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological response. J Clin Oncol 6:329-337, 1988
9. Burgers JM, van Glabbeke M, Busson A, et al: Osteosarcoma of the limbs. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer 61:1024-1031, 1988
10. French Bone Tumor Study Group: Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. Cancer 61:1304-1311, 1988
11. Bacci G, Picci P, Ruggieri P, et al: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65:2539-2553, 1990
12. Hudson M, Jaffe MR, Jaffe N, et al: Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 8:1988-1997, 1990
13. Winkler K, Bieling P, Bielack S, et al: Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop 270:79-86, 1991
14. Bieling P, Bielack S, Delling G, et al: Neoadjuvant chemotherapy of osteosarcoma. Preliminary results of the cooperative COSS-86 osteosarcoma study. Klin Padiatr 203:220-230, 1991
15. Bacci G, Picci P, Pignatti G, et al: Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities. Clin Orthop 87-98, 1991
16. Jaffe N, Smith D, Jaffe MR, et al: Intraarterial cisplatin in the management of stage HB osteosarcoma in the pediatric and adolescent age group. Clin Orthop 15-21, 1991
17. Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 10:5-15, 1992
18. Glasser DB, Lane JM, Huvos AG, et al: Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 69:698-708, 1992
19. Bramwell VHC, Burgers M, Sneath R, et al: A comparison of two short intensive chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. J Clin Oncol 10:1579-1591, 1992
20. Geidel S, Garn M, Gravinghoff L, et al: Cardiomyopathy after osteosarcoma treatment: A contribution to the cardiotoxicity of adriamycin. Klin Padiatr 203:257-261, 1991
21. Taylor WF, Ivins JC, Pritchard DJ, et al: Trends and variability in survival among patients with osteosarcoma: A 7-year update. Mayo Clin Proc 60:91-104, 1985
22. Bentzen SM, Poulsen HS, Kaae S, et al: Prognostic factors in osteosarcomas: A regression analysis. Cancer 62:194-202, 1988
23. Taylor WF, Ivins JC, Unni KK, et al: Prognostic variables in osteosarcoma: A multi-institutional study. J Natl Cancer Inst 81:21-30, 1989
24. Davis AM, Bell RS, Goodwin PJ: Prognostic factors in osteosarcoma: a Critical review. J Clin Oncol 12:423-431, 1994
25. Edmonson JH, Green SJ, Ivins JC, et al: A controlled study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2:152-156, 1984
26. Spanier SS, Shuster JJ, Vander Griend RA: The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 72:643-653, 1990
27. Petrilli S, Gentil FC, Epelman S, et al: Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 68:733-737, 1991
28. Springfield DS, Schakel MEJ, Spanier SS: Spontaneous necrosis in osteosarcoma. Clin Orthop 233-237, 1991
29. Salzer-Kuntschik M, Brand G, Delling G: Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 4:135-141, 1983
30. Winkler K, Bielack S, Delling G, et al: Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 66:1703-1710, 1990
31. BMDP Statistical Software Inc: BMDP Statistical Software Manual. Los Angeles, CA: University of California, 1988
32. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
33. Cox DR: Regression models and life table (with discussion). J R Stat Soc B 34:187-220, 1972
34. Rehan N, Bieling P, Winkler P, et al: Die prognostische Bedeutung des Tumorvolumens beim Osteosarkom unter neoadjuvanter Chemotherapie. Klin Padiatr 205:200-209, 1993
35. Baldini N, Manconi VG: Evaluation of tumor volume in osteosarcoma. Proceedings of the Osteosarcoma Research Conference, Pittsburgh, PA, October 16-18, 1992 (abstr)
36. Scranton PE, DeCicco FA, Totten RS, et al: Prognostic factors in osteosarcoma: A review of 20 years experience at the University of Pittsburgh Health Center Hospitals. Cancer 36:2179-2191, 1975
37. Uribe Botero G, Russell WO, Sutow WW, et al: Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol 67:427-435, 1977
38. Larsson SE, Lorentzon R, Wedren H, et al: The prognosis in osteosarcoma. Int Orthop 5:305-310, 1981